Lakshmi KhandkeSenior Program Advisor, Center for Vaccine Innovation & Access at PATH
Lakshmi Khandke, PhD, is Senior Program Advisor at the Center for Vaccine Innovation and Access at PATH. Dr Khandke’s current role at PATH is multifaceted to provide leadership within the Chemistry, Manufacturing and Control team by providing oversight and support to partners to accelerate the development and introduction of lifesaving vaccines for optimal public health impact in the world’s lowest resource settings.
Prior to joining PATH, she was the Director for Drug Product Development within global Vaccines, Pfizer’s Worldwide Research and Development organization to develop first-in-class or best-in-class vaccines to prevent or treat diseases of significant unmet medical need. Her accomplishments have been part of the global licensures of Prevenar 7, Prevenar13® and Prevenar 13 multidose to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B. She has been responsible for the drug product development of several bacterial and viral vaccine programs (Clostridium difficile, Group B Streptococcus, Staphylococcus aureus, HIV, Herpes Simplex virus, polio, and Respiratory Syncytial virus). Before the acquisition of Wyeth by Pfizer in 2009, where she directed or supported number vaccine efforts in process, analytical and formulation development.
Dr Khandke received her Ph.D. from the University of Bombay in Biochemistry following which she did her postdoctoral fellowship at the Rockefeller University in New York.